Together Beyond COVID-19
PharmaLex.perts Jürgen Hönig and Lisa Pascoe discuss the challenges COVID-19 has placed on the pharma industry – from R&D to clinical trials and manufacturing to drug safety – and how companies like PharmaLex are working together with the industry to ensure regulatory compliance.
Posted:
ReadIs there a way of safeguarding the supply of medicines in the case of a ‘no deal’ Brexit?
Jonathan Trethowan looks at how we can safeguard our supply of medicines in the case of ‘no deal’ Brexit
Posted:
ReadBrexit Uncertainty - impact on medicines supply
PharmaLex Vice President Regulatory and Scientific Policy, Jonathan Trethowan looks at what impact Brexit might have on medicines supply across the EU
Posted:
ReadThe Pink Sheet - Big Data: Moving From Artificial Trials To A Smarter Regulatory Process
PharmaLex’s Bruno Boulanger discusses the impact big data will have on how the pharmaceutical industry gathers and delivers data in the future. *subscription required*
Posted:
ReadThe 5 things you want to know about Artificial Intelligence
PharmaLex CEO, Tilo Netzer explains the five things you should know about Artificial Intelligence
Posted:
Read